lifileucel + nivolumab + relatlimab

This is a **combination therapy** consisting of three agents: - **Lifileucel** is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, where T cells are harvested from a patient’s tumor, expanded ex vivo, and reinfused to target a broad range of patient-specific tumor neoantigens. - **Nivolumab** is a fully human monoclonal antibody targeting the programmed death 1 (PD-1) immune checkpoint receptor, blocking its interaction with ligands PD-L1/PD-L2 and thereby enhancing T-cell activation and anti-tumor immunity. - **Relatlimab** is a monoclonal antibody targeting lymphocyte-activation gene 3 (LAG-3), a negative immune checkpoint regulator, relieving inhibition of T lymphocytes and promoting anti-tumor response. The combination aims to leverage adoptive cell therapy with checkpoint inhibition for synergistic activation of the immune response, primarily evaluated in advanced melanoma refractory to other immunotherapies[2][3][5].

Brand names

AmtagviOpdualag

Other names

lifileucel + nivolumab + relatlimab combinationTIL + nivolumab + relatlimab